nach oben

Medical Oncology

Erschienen in:

01.11.2016 | Original Paper

The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer

verfasst von: Yongyong Xi, Liang wang, Chengcao Sun, Cuili Yang, Feng Zhang, Dejia Li

Erschienen in: Medical Oncology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidences suggest that lots of microRNAs (miRNAs) play crucial roles in (patho-)physiological processes of lung cancer, including metastasis, drug-resistance or tumorigenesis. They mediate the progression of cell growth, migration and invasion by regulating the expression of special genes. MiRNA expression patterns could also serve as diagnostic/prognostic biomarkers. Cancer therapies mediated by miRNAs remain tremendous potential and challenges. Our previous small RNA-seq assay found that the novel miR-9501 was down-regulated in lung cancer tissues compared with adjacent non-cancer tissues. In this study, our results verified that miR-9501 was significantly down-regulated in lung cancer tissues and its expression levels were remarkably suppressed in non-small cell lung cancer cell lines. Then, we characterized and investigated the novel miR-9501 in A549 cells. Transient transfection of miR-9501 into cultured A549 cells led to remarkable decrease in cell proliferation, migration and increase apoptosis. These data demonstrated that miR-9501 might be a tumor suppressor for lung cancer therapy.

Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.CrossRefPubMedCentral

Zhang Y, Han L, Pang J, Wang Y, Feng F, Jiang Q. Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis. Tumour Biol. 2016;37(6):8259–70.CrossRefPubMed

National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The national lung screening trial: overview and study design. Radiology. 2011;258(1):243–53.CrossRefPubMedCentral

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64.CrossRefPubMed

Leidinger P, Brefort T, Backes C, Krapp M, Galata V, Beier M, Kohlhaas J, Huwer H, Meese E, Keller A. High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Oncotarget. 2016;7(4):4611–23.PubMed

Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y, Wang L, Wang S, He Q, Huang J, Xie S, Jiang W, Li D. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 2015;6(28):25533–74.CrossRefPubMedPubMedCentral

Vrijens K, Bollati V, Nawrot TS. MicroRNA as potential signatures of environmental exposure or effect: a systematic review. Environ Health Perspect. 2015;123(5):399–411.PubMedPubMedCentral

Del Vescovo V, Grasso M, Barbareschi M, Denti MA. MicroRNA as lung cancer biomarkers. World J Clin Oncol. 2014;5(4):604–20.CrossRefPubMedPubMedCentral

Bhatt K, Lanting LL, Jia Y, Yadav S, Reddy MA, Magilnick N, Boldin M, Natarajan R. Anti-inflammatory role of MicroRNA-146a in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol. 2016;27(8):2277–88.CrossRefPubMed

10.

Green D, Dalmay T, Fraser WD. Role of miR-140 in embryonic bone development and cancer. Clin Sci (Lond). 2015;129(10):863–73.CrossRef

11.

Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer. 2014;85(2):306–13.CrossRefPubMed

12.

Hu JY, Yi W, Zhang MY, Xu R, Zeng LS, Long XR, Zhou XM, Zheng XS, Kang Y, Wang HY. MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. Oncol Lett. 2016;11(3):2155–63.PubMedPubMedCentral

13.

Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D’Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM. MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci USA. 2015;112(48):14924–9.CrossRefPubMedPubMedCentral

14.

Yang C, Sun C, Liang X, Xie S, Huang J, Li D. Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer Gene Ther. 2016;23(4):90–7.CrossRefPubMed

15.

Khanmi K, Ignacimuthu S, Paulraj MG. MicroRNA in prostate cancer. Clin Chim Acta. 2015;451(Pt B):154–60.CrossRefPubMed

16.

Sun CC, Li SJ, Zhang F, Pan JY, Wang L, Yang CL, Xi YY, Li DJ. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget. 2016. doi:10.18632/oncotarget.7517.

17.

Huang J, Sun C, Wang S, He Q, Li D. MicroRNA miR-10b inhibition reduces cell proliferation and promotes apoptosis in non-small cell lung cancer(NSCLC) cells. Mol BioSyst. 2015;11(7):2051–9.CrossRefPubMed

18.

Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang R, Huang P, Yin Y, Shu Y. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 2012;279(20):3800–12.CrossRefPubMed

19.

Shen G, Rong X, Zhao J, Yang X, Li H, Jiang H, Zhou Q, Ji T, Huang S, Zhang J, Jia H. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis. 2014;35(12):2748–55.CrossRefPubMed

20.

Qu J, Li M, An J, Zhao B, Zhong W, Gu Q, Cao L, Yang H, Hu C. MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin/ZEB1 signaling. Int J Oncol. 2015;47(6):2141–52.PubMed

21.

He Q, Ren X, Chen J, Li Y, Tang X, Wen X, Yang X, Zhang J, Wang Y, Ma J, Liu N. MiR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways. Oncotarget. 2016;7(3):3047–58.PubMed

22.

Zhou YL, Xu YJ, Qiao CW. MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 2015;8(6):6312–22.PubMedPubMedCentral

23.

Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, Li J, He X, Yao M. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 2015;34(4):413–23.CrossRefPubMed

24.

Yoo JK, Jung HY, Lee JM, Yi H, Oh SH, Ko HY, Yoo H, Kim HR, Song H, Kim S, Kim JK. The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1. Cell Death Differ. 2014;21(7):1150–9.CrossRefPubMedPubMedCentral

25.

Li TJ, Chen YL, Gua CJ, Xue SJ, Ma SM, Li XD. MicroRNA 181b promotes vascular smooth muscle cells proliferation through activation of PI3K and MAPK pathways. Int J Clin Exp Pathol. 2015;8(9):10375–84.PubMedPubMedCentral

26.

Yu J, Tan Q, Deng B, Fang C, Qi D, Wang R. The microRNA-520a-3p inhibits proliferation, apoptosis and metastasis by targeting MAP3K2 in non-small cell lung cancer. Am J Cancer Res. 2015;5(2):802–11.PubMedPubMedCentral

27.

Wang M, Ge X, Zheng J, Li D, Liu X, Wang L, Jiang C, Shi Z, Qin L, Liu J, Yang H, Liu LZ, He J, Zhen L, Jiang BH. Role and mechanism of miR-222 in arsenic-transformed cells for inducing tumor growth. Oncotarget. 2016. doi:10.18632/oncotarget.7525.

28.

Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, Zhang F, Fu Y, Li D. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget. 2016. doi:10.18632/oncotarget.7071.

29.

Zhang T, Hu Y, Ju J, Hou L, Li Z, Xiao D, Li Y, Yao J, Wang C, Zhang Y, Zhang L. Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D. Sci Rep. 2016;6:19346.CrossRefPubMedPubMedCentral

30.

Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, Li D. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 2015;6(37):39756–92.PubMedPubMedCentral

31.

Li JW, He SY, Feng ZZ, Zhao L, Jia WK, Liu P, Zhu Y, Jian Z, Xiao YB. MicroRNA-146b inhibition augments hypoxia-induced cardiomyocyte apoptosis. Mol Med Rep. 2015;12(5):6903–10.PubMed

Titel: The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer
verfasst von: Yongyong Xi
Liang wang
Chengcao Sun
Cuili Yang
Feng Zhang
Dejia Li
Publikationsdatum: 01.11.2016
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 11/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-016-0837-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer

Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma

7SK small nuclear RNA transcription level down-regulates in human tumors and stem cells

PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors

Correlation between indoleamine 2,3 dioxygenase mRNA and CDKN2A/p16 mRNA: a combined strategy to cervical cancer diagnosis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie